Navigation Links
VAP(R) Cholesterol Test Bolsters Biophysical(R) Health Assessment
Date:7/31/2008

Biophysical Corporation adds advanced cholesterol testing capabilities

BIRMINGHAM, Ala., July 31 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced that its VAP(R) Cholesterol Test is now included in Biophysical Corporation's newly released health assessment, BiophysicalCheck.

The announcement means that the VAP Test, with its unique ability to identify far more areas of risk than the standard lipid panel, will now be available in Biophysical's biomarker-based health assessment.

"The advanced cholesterol testing made possible by the VAP Test is a perfect and natural fit for Biophysical," said Atherotech Chief Medical Officer James Ehrlich, M.D. "It is certainly rewarding to be included in the offering of a company that brings so much expertise to the field of biomarkers and early detection."

The BiophysicalCheck is based on the technology used in the company's flagship test, the Biophysical250. This test has been called "The Ultimate Blood Test" by Scientific American and has been featured on highly-rated U.S. syndicated talk shows. The company anticipates adding the VAP Test to its other assessments later this year.

"The addition of the VAP Test strengthens even further our ability to detect cardiovascular disease at an earlier, more preventable stage," said George Rodgers, M.D., chief medical officer and president of Biophysical Corporation. "We're pleased to incorporate the VAP Test's expanded cholesterol testing into our biomarkers for the pre-symptomatic detection of disease."

The VAP Test directly measures LDL and has been shown to identify a far greater number of patients with lipid abnormalities than the standard lipid panel (cholesterol and triglyceride test). The test also reports 15 separate components versus four in the standard cholesterol test.

Consumers, corporations, physicians and wellness centers interested in learning more about the VAP Test can visit http://www.thevaptest.com and/or the Biophysical Corporation and its biomarker-based health assessments at http://www.biophysicalcorp.com or call 800.532.7092.

About Biophysical Corporation

Biophysical Corporation is a private, Austin, Texas-based company dedicated to advancing clinical knowledge and quality of life for its clients. Formed in 2004, the company offers Biophysical250, the most comprehensive and advanced assessment of personal health ever developed. Through the innovative analysis of blood-based biomarkers, Biophysical250 may indicate the presence or risk of cancer, cardiovascular disease and other health risks often before symptoms appear. The company's management and advisory board includes internationally renowned physicians and scientists who are leaders in the field of biomarker research. More information about the company and Biophysical250 is available at http://www.biophysicalcorp.com or by calling 800.532.7092.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on direct measurement of the comprehensive lipid panel using the company's patented VAP technology, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for LDL measurement and the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Cholesterol Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit http://www.thevaptest.com.

Biophysical is a registered trademark of Biophysical Corporation. Biophysical250 and BiophysicalCheck are trademarks of Biophysical Corporation.


'/>"/>
SOURCE Atherotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
2. New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl)
3. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
4. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
5. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
6. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
7. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
8. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
9. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
10. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
11. Cardinal Health, Prime Therapeutics Sign Primary Distribution Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... development of innovative products and services, announced today that ... denied its petition to review decisions by ... Patent No. 6,258,540 (",540 Patent") are not patent eligible ... Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  In ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):